| 1. |
- Eriksson, Leif A., 1964-, et al.
(författare)
-
Tetrazole derivatives as cytochrome p450 inhibitors
- 2019
-
Patent (populärvet., debatt m.m.)abstract
- According to the invention there is provided a compound of formula I, wherein R1 and R2 have meanings given in the description, which compounds are useful in the treatment of skin disorders and other diseases.
|
|
| 2. |
- Andersson, Sören, 1957-, et al.
(författare)
-
CHIMERIC MOMP ANTIGEN
- 2015
-
Patent (populärvet., debatt m.m.)
|
|
| 3. |
- Ragno, Rino, et al.
(författare)
-
Structure-based modeling and target-selectivity prediction
- 2014
-
Patent (populärvet., debatt m.m.)abstract
- The present invention provides, inter alia, methods, models, and systems for selecting an effector having specificity for a target molecule. The methods and systems of the present invention involve several steps, including compiling a database containing structural data for a library of molecules and a population of ligands and activity data, establishing structure-based equivalence of sequence elements in the library of molecules, determining likely spatial orientations of population ligands in library molecules, calculating interaction energies for each ligand-molecule pair, generating statistical models that are predictive of sequence elements likely to contribute to a differential effect of ligands on molecules, selecting an effector that is likely to have a desired specificity for the target molecule, experimentally determining activity data for effector-library molecule pairs, and at least once repeating the steps listed above wherein the effector is a member of the population of ligands.
|
|
| 4. |
- Hedhammar, My, et al.
(författare)
-
Spider silk fusion protein structures for binding to an organic target
- 2012
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- A protein structure capable of selective interaction with an organic target is provided. The protein structure is a polymer comprising as a repeating structural unit a recombinant fusion protein that is capable of selective interaction with the organic target. The fusion protein is comprising the moieties B, REP and CT, and optionally NT. B is a non-spidroin moiety of more than 30 amino acid residues, which provides the capacity of selective interaction with the organic target. REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. NT is an optional moiety of from 100 to 160 amino acid residues and is derived from the N-terminal fragment of a spider silk protein. The fusion protein and protein structure thereof is useful as an affinity medium and a cell scaffold material.
|
|
| 5. |
- Almhöjd, Ulrica S., et al.
(författare)
-
Preparation for treatment of wounds and sores comprising hypochlorite and amino acids : WO 2014016157
- 2014
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- A kit of parts for use in prevention and/or treatment of sores, wounds, ulcers or the like, or a fistula or otitis. The kit of parts comprises a first aqueous component comprising one or more amino acids, and a second aqueous component comprising an active halogen compound, wherein the pH of the first component and/or the second component is about 9 to 11.5. There is also provided a treatment preparation prepared from the components and uses thereof in the prevention and/or treatment of sores, wounds, ulcers or the like, or a fistula or otitis.
|
|
| 6. |
- Bidarian-Moniri, Armin
(författare)
-
Device for Equalization of the Pressure in the Middle Ear
- 2013
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- Device for the equalization of middle ear pressure for non-surgical ventilation of the middle ear for treatment of otitis media with effusion/serous otitis media in infants, children and adults.
|
|
| 7. |
|
|
| 8. |
- Aahlin, Kristofer, et al.
(författare)
-
Preparation of 1-(4-(5-amino-6-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-yl)benzoyl)piperazine derivatives as glycogen synthase kinase 3 inhibitors.
- 2011
-
Patent (populärvet., debatt m.m.)abstract
- Title compds. I [R1 = H or Me], and their pharmaceutically acceptable salts, are prepd. and disclosed as glycogen synthase kinase 3 (GSK3) inhibitors. Thus, e.g., II was prepd. by cyclization of 3-amino-N-(4-hydroxypyridin-3-yl)pyrazine-2-carboxamide (prepn. given) to get intermediate 3-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-amine, which underwent bromination followed by Suzuki reaction with (4-methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone. Compds. of the invention were tested for their selective inhibitory activity of GSK3β, e.g., II exhibited Ki value of 2.3 nM. The invention compds. are useful for the treatment of cognitive disorders, diabetes, cancer, etc. [on SciFinder(R)]
|
|
| 9. |
- Antonov, D, et al.
(författare)
-
HCV inhibiting macrocyclic phenylcarbamates
- 2008
-
Patent (populärvet., debatt m.m.)abstract
- Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
|
|
| 10. |
- Arvidsson, Per I., et al.
(författare)
-
Preparation of imidazolylpyrimidine derivatives for treatment of glycogen synthase kinase 3 related disorders such as Alzheimer's disease.
- 2010
-
Patent (populärvet., debatt m.m.)abstract
- Title compds. I [R1 = H or F; R2 and R3 independently = H or Me], and their pharmaceutically acceptable salts, are prepd. and disclosed as agents for treatment of glycogen synthase kinase 3 (GSK3) related disorders such as Alzheimer's disease. Thus, e.g., II.HCl was prepd. by reductive amination of 4-bromo-3-fluorobenzaldehyde with (S)-3-methylmorpholine followed by amination with 2-amino-5-fluoro-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidine. Select I were evaluated for GSK3β inhibitory activity, and e.g., II·HCl demonstrated a Ki value of 30 nM. [on SciFinder(R)]
|
|
